Search

Your search keyword '"Ilaria Lenci"' showing total 41 results
Start Over Author "Ilaria Lenci" Journal digestive and liver disease
41 results on '"Ilaria Lenci"'

1. Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature

Author

Federica Invernizzi, Lucia Lapenna, Valentina Cossiga, Ilaria Lenci, C. Becchetti, Filomena Morisco, Alberto Zanetto, Patrizia Burra, Luisa Pasulo, Maria Guarino, Bruna Lavezzo, and Manuela Merli

Subjects
Liver Cirrhosis, Male, Sarcopenia, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.medical_treatment, Liver transplantation, Chronic liver disease, Muscle mass, Liver disease, Quality of life, Internal medicine, gender, medicine, sex, Humans, Retrospective Studies, Hepatology, business.industry, Incidence (epidemiology), Liver Neoplasms, Gastroenterology, musculoskeletal system, medicine.disease, body regions, Hepatocellular carcinoma, Quality of Life, Female, 610 Medizin und Gesundheit, liver disease, business, human activities, sarcopenia
Abstract

Sarcopenia, defined as progressive and generalized loss of muscle mass and strength, is common in chronic liver disease. It significantly impacts the quality of life and increases the risk of liver-related complications and mortality in cirrhotic patients. Moreover, recent studies showed a negative impact of sarcopenia on patients awaiting liver transplantation (LT), on post-LT outcomes, and on response to hepatocellular carcinoma therapies. Data about the influence of sex on the incidence, prevalence, diagnosis and treatment of sarcopenia in chronic liver diseases are poor and conflicting. The aims of this review of the literature are to define sex differences in sarcopenic cirrhotic patients and to highlight the necessity of a sex stratified analysis in future studies. This analysis of the literature showed that most of the studies are retrospective, with a higher prevalence of sarcopenia in males, probably due to anatomical differences between the sexes. Moreover, diagnostic criteria for sarcopenia are different between studies, as there is not a defined cut-off and, as a consequence, no comparable results. In conclusion, sex seems to have an impact on sarcopenia, and future studies must accurately investigate its role in identifying and treating high-risk patients, reducing the negative impact of sarcopenia on the survival and quality of life of cirrhotic patients.

Published
2022
Full Text
View/download PDF

2. Pregnancy after liver transplantation: a survey from Italian liver transplants centres

Author

Simona Marenco, Lucia Lapenna, Manuela Merli, Erica Villa, Francesco Russo, L. Trespidi, P. Burra, Sofia Volpato, A.Galeota Lanza, N. De Maria, I.G. Ramezzana, Erida Nure, U. Cillo, Luisa Pasulo, Maria Francesca Donato, P. Bo, Alberto Ferrarese, Patrizia Boccagni, A.W. Avolio, S.S. Sciarrone, Erich Cosmi, L. Mameli, Marco Maria Pascale, Federica Invernizzi, Sherrie Bhoori, Pierluigi Toniutto, Stefano Fagiuoli, Ilaria Lenci, and R. Di Donato

Subjects
medicine.medical_specialty, Pregnancy, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, Liver transplantation, Liver transplants, business, medicine.disease, Surgery
Published
2021
Full Text
View/download PDF

3. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Mario Starace, Valerio Giannelli, Nunzia Cuomo, Vanni Borghi, Aldo Bertoli, Anna Licata, Anna Claudia Pellicelli, C. Minichini, M. Andreoni, M. Di Stefano, Giuseppe Cariti, Enzo Boeri, Raffaele Cozzolongo, Roberto Gulminetti, E. Milano, Valeria Cento, Elisabetta Degasperi, Laura Sighinolfi, A. Raddi, Ivana Maida, Barbara Rossetti, Teresa Santantonio, Valeria Micheli, C. Masetti, P. Andreone, Giustino Parruti, F. Di Lorenzo, Ilaria Lenci, Tiziano Allice, Annapaola Callegaro, Elisa Biliotti, M. Lichtner, Teresa Pollicino, Pietro Lampertico, Gloria Taliani, Caterina Pasquazzi, Piero Colombatto, Alessia Giorgini, G. Raimondo, Antonio Craxì, Francesca Ceccherini-Silberstein, Filomena Morisco, Valeria Ghisetti, V.C. Di Maio, Giuliano Rizzardini, Silvia Galli, Stefania Paolucci, A. De Santis, A. Lleo, Vincenzo Sangiovanni, A. Ciancio, Maurizio Zazzi, Elisabetta Teti, Simona Marenco, William Gennari, Stefano Novati, Giovanni Cenderello, Simona Landonio, Manuela Merli, A. Scuteri, Nicola Coppola, C.F. Perno, Giulia Morsica, I. Beretta, Claudio Maria Mastroianni, Simona Francioso, Mario Angelico, Laura Ambra Nicolini, Chiara Dentone, Silvia Barbaliscia, G.B. Gaeta, Marianna Aragri, Ennio Polilli, L. Donnarumma, Vincenza Calvaruso, Bianca Bruzzone, Fausto Baldanti, V. Pace Palitti, Roberto Ganga, Maurizia Rossana Brunetto, C. Paternoster, Sergio Babudieri, M. Puoti, Hamid Hasson, and M. Rendina

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, NS5A
Published
2020
Full Text
View/download PDF

4. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Pietro Lampertico, Valeria Cento, Claudio Maria Mastroianni, M. Puoti, Giuliano Rizzardini, Maurizio Zazzi, M. Lichtner, Bianca Bruzzone, Ivana Maida, Elisabetta Degasperi, C.F. Perno, M. Rendina, Giustino Parruti, Vincenza Calvaruso, Gloria Taliani, F. Di Lorenzo, Ilaria Lenci, Anna Claudia Pellicelli, Caterina Pasquazzi, Stefania Paolucci, A. Raddi, Marianna Aragri, Ennio Polilli, Giulia Morsica, Mario Starace, M. Andreoni, M. Di Stefano, C. Minichini, L. Donnarumma, V. Guarneri, Simona Marenco, Simona Landonio, Raffaele Cozzolongo, V. Pace Palitti, N. Cuomo, P. Andreone, Nicola Coppola, Silvia Galli, Mario Angelico, C. Paternoster, Roberto Ganga, Vanni Borghi, Elisabetta Teti, Sergio Babudieri, Silvia Barbaliscia, Anna Licata, Giovanni Cenderello, Antonio Craxì, Filomena Morisco, Maurizia Rossana Brunetto, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Piero Colombatto, Valeria Micheli, Teresa Pollicino, Laura Ambra Nicolini, Alessia Giorgini, Valeria Ghisetti, S. Novati, Annapaola Callegaro, Aldo Bertoli, E. Milano, Roberto Gulminetti, A. De Santis, F. Ceccherini-Silberstein, Teresa Santantonio, C. Masetti, G. Raimondo, Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Subjects
Resistance test, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DAA failur, Vironet C, NS5A, Regimen, Internal medicine, medicine, retreatment, business
Abstract

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.

Published
2019
Full Text
View/download PDF

5. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Author

V. Boccaccio, Irene Maida, Ennio Polilli, Alessandro Ciaccio, Ilaria Lenci, Anna Claudia Pellicelli, Marilena Rendina, Fabio Niero, Guido Gubertini, Mario Angelico, T. Ruggiero, Stefano Bonora, Barbara Rossetti, Caterina Pasquazzi, Niccolò Gabriele Coppola, Simona Francioso, Silvia Barbaliscia, M. Puoti, M. Andreoni, L. Foroghi, L. Sarmati, Silvia Paolucci, Giuliana Fiorentino, Teresa Pollicino, G.B. Gaeta, C.F. Perno, Giustino Parruti, Valeria Cento, Laura Ambra Nicolini, Gloria Taliani, Elisabetta Teti, Lucio Boglione, Asia Bertoli, Sergio Babudieri, Valeria Micheli, Renato Maserati, Marianna Aragri, F. Ceccherini-Silberstein, Vincenzo Vullo, A. R. D’Ambrosio, Simona Marenco, A. Lleo, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Vincenzo Sangiovanni, Maurizio Zazzi, Vincenza Calvaruso, Alessia Ciancio, V. Pace Palitti, Bianca Bruzzone, and Giacomo Raimondo

Subjects
Hepatology, business.industry, Gastroenterology, Medicine, business, Virology
Published
2018
Full Text
View/download PDF

6. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

Author

Ilaria Lenci, A. Di Biagio, Giuliano Rizzardini, L. Marinaro, C. D'Ambrosio, Fausto Baldanti, Ivana Maida, G.B. Gaeta, M. Puoti, T. Ruggiero, Mario Angelico, Vincenza Calvaruso, Laura Sticchi, Mario Starace, Giustino Parruti, P. Cacciatore, Nicola Caporaso, Caterina Pasquazzi, Stefania Paolucci, Anna Claudia Pellicelli, M. Andreoni, C. Masetti, Sergio Babudieri, Gabriella d'Ettorre, Francesco Santopaolo, Raffaele Cozzolongo, P. Andreone, Carlo Magni, Valeria Cento, Guido Gubertini, J. Vecchiet, Stefano Novati, Nicola Coppola, C.F. Perno, Bianca Bruzzone, F. De Leonardis, V. Pace Palitti, Marianna Aragri, A. Grieco, Pierluigi Tarquini, G. De Stefano, G. Raimondo, Teresa Pollicino, Alessia Giorgini, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, M.C. Sorbo, Savino Bruno, M. Paoloni, F. Ceccherini-Silberstein, Roberto Gulminetti, Antonio Craxì, Filomena Morisco, Manuela Merli, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Simona Francioso, Simona Landonio, Aldo Bertoli, A. Mancon, Valeria Micheli, Antonio Picciotto, V. Boccaccio, M. Melis, Ennio Polilli, F.P. Antonucci, Dante Romagnoli, and Silvia Barbaliscia

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Interferon free, Gastroenterology, DIRECT ACTING ANTIVIRALS, 03 medical and health sciences, 0302 clinical medicine, Second line, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In real life, 030211 gastroenterology & hepatology, business
Published
2017
Full Text
View/download PDF

7. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens

Author

S. Di Nardi, D. Di Paolo, A. Pecchioli, C. Masetti, A. Brega, Francesco Santopaolo, Ilaria Lenci, F. De Leonardis, Martina Milana, T. Marianelli, F. Antenucci, Mario Angelico, A. Bosa, Leonardo Baiocchi, Plinio Rossi, and Simona Francioso

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cohort, Gastroenterology, medicine, Portal hypertension, medicine.disease, business, Surgery
Published
2017
Full Text
View/download PDF

8. Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis

Author

Carlo Federico Perno, F. Marcuccilli, Ilaria Lenci, Daniele Di Paolo, Mario Angelico, Laura Tariciotti, Marco Ciotti, Giuseppe Tisone, and Tania Guenci

Subjects
Liver Cirrhosis, Male, HBsAg, Cirrhosis, medicine.medical_treatment, Liver transplantation, medicine.disease_cause, Gastroenterology, circular, Recurrence, Secondary Prevention, Medicine, hepatitis b, Survivors, immunosuppression, Vaccination, virus diseases, Immunosuppression, cccDNA, Middle Aged, Hepatitis B, Settore MED/07 - Microbiologia e Microbiologia Clinica, male, vaccination, antiviral agents, middle aged, liver cirrhosis, DNA, viral, female, hepatocytes, liver transplantation, humans, hepatitis B virus, liver, survivors, aged, adult, DNA, circular, hepatitis b, chronic, chronic, Liver, Female, Hepatitis D virus, DNA, Circular, viral, Adult, Hepatitis B virus, medicine.medical_specialty, Antiviral Agents, Hepatitis B, Chronic, Internal medicine, Humans, Aged, Immunosuppression Therapy, Hepatology, business.industry, DNA, medicine.disease, digestive system diseases, Liver Transplantation, Settore MED/18 - Chirurgia Generale, DNA, Viral, Immunology, Hepatocytes, business
Abstract

Background Life-long prophylaxis against HBV recurrence is recommended in patients transplanted for HBV-related disease. The risk of HBV reactivation is due to persistence of covalently closed circular (ccc) DNA in hepatocytes. Whether cccDNA persists in livers of long-term transplant survivors who received conventional prophylaxis is unknown. Aim To investigate the presence of intrahepatic total and cccDNA in transplanted patients with no evidence of biochemical markers of HBV recurrence. Methods Intrahepatic total and cccDNA were assessed using sensitive nested and real-time PCR from 44 HBsAg-positive patients (75% male; mean age 55.2 ± 8.9 years) who had undetectable serum HBV-DNA at transplant. The mean follow-up after transplant was 88.3 months (range, 18–159). Results One patient underwent HBV recurrence after transplant and was the only who tested positive for both intrahepatic total HBV-DNA and cccDNA. Of the 43 patients negative for all serological markers of HBV infection, only 2 tested positive for intrahepatic total HBV-DNA, but none for cccDNA. Conclusions Most patients with undetectable HBV-DNA at transplant, who received conventional HBV prophylaxis, have no evidence of intrahepatic total HBV-DNA and cccDNA. cccDNA should be considered a new additional diagnostic tool, also to identify patients at low risk of HBV recurrence after liver transplantation.

Published
2010
Full Text
View/download PDF

9. Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels

Author

Mario Angelico, A. Galante, Simona Francioso, D. Di Paolo, Ilaria Lenci, and Paola Piccolo

Subjects
Male, medicine.medical_specialty, Myocardial Ischemia, Alpha interferon, Interferon alpha-2, Antiviral Agents, Risk Assessment, Severity of Illness Index, Gastroenterology, Drug Administration Schedule, Polyethylene Glycols, Electrocardiography, chemistry.chemical_compound, Pharmacotherapy, Liver Function Tests, Recurrence, Internal medicine, Ribavirin, Severity of illness, medicine, Humans, cardiovascular diseases, Monitoring, Physiologic, Dose-Response Relationship, Drug, Hepatology, medicine.diagnostic_test, biology, business.industry, Interferon-alpha, Alanine Transaminase, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Recombinant Proteins, Surgery, Alanine transaminase, chemistry, biology.protein, Drug Therapy, Combination, Liver function tests, business, Follow-Up Studies
Abstract

A 63-year-old man with chronic hepatitis C and persistently normal alanine aminotransferase levels was treated with peginterferon alpha-2a (180 microg weekly) and ribavirin (800 mg daily). Hepatitis C virus-ribonucleic acid was negative at week 4. After 12 weeks of therapy, haemoglobin levels had decreased by 3.5mg/dL, and he developed a syncope episode with electrocardiographic signs of myocardial ischaemia. Antiviral treatment was stopped and the ischaemia-like electrocardiographic changes resolved completely within 2 months. Eight months later, because of the previous rapid virological response and patient motivation, he was treated again with peginterferon and ribavirin. Baseline and weekly electrocardiographic recordings were obtained during treatment. At week 4 hepatitis C virus-ribonucleic acid was negative. At week 8, when the haemoglobin levels had decreased by 3.4 mg/dL, the patient developed the same ischaemia-like changes that occurred during the previous treatment. Antiviral therapy was stopped and the electrocardiographic ischaemia-like changes disappeared after 1 month. The patient neither had a history of previous cardiovascular diseases, nor evidence of current disease at myocardial scintigraphy. However, a coronary microvessel spasm, possibly related to drug-toxicity and/or anaemia could not be excluded. This case indicates the need of strict electrocardiographic monitoring in elderly patients undergoing treatment with peginterferon and ribavirin.

Published
2008
Full Text
View/download PDF

10. Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins

Author

Ilaria Lenci, M.O. Trinito, G. Tisone, D. Di Paolo, Mario Angelico, Marco Carbone, and C. Longhi

Subjects
Adult, Male, HBsAg, Cirrhosis, Vaccination schedule, medicine.medical_treatment, Immunoglobulins, Liver transplantation, medicine.disease_cause, Hepatitis B Antibodies, Humans, Hepatitis B, Lamivudine, Hepatitis B Vaccines, Middle Aged, Liver Transplantation, Reverse Transcriptase Inhibitors, medicine, Hepatitis B virus, Settore MED/12 - Gastroenterologia, Hepatology, business.industry, Gastroenterology, medicine.disease, Vaccination, Settore MED/18 - Chirurgia Generale, Immunology, business, medicine.drug
Abstract

Background The recommended prophylaxis against hepatitis B virus recurrence after liver transplantation based on hepatitis B immunoglobulins and lamivudine is highly expensive. A recent study reported a significant anti-HBs (antibodies against hepatitis B surface antigen) response after a reinforced vaccination against hepatitis B virus, a result not confirmed in a study from our group. Concomitant lamivudine treatment and the achievement of complete washout of anti-hepatitis B-specific immunoglobulin prior to vaccination in our study could explain the contradiction. Aims To test the efficacy of a reinforced anti-hepatitis B virus vaccination schedule without lamivudine and without previous anti-hepatitis B-specific immunoglobulin washout. Methods A double reinforced course of S-recombinant hepatitis B virus vaccination was given to seven male patients who were transplanted for hepatitis B virus-related cirrhosis. Vaccination consisted of two cycles of three intramuscular double doses (40 μg), given at month 0, 1, 2, and 3, 4, 5, respectively. The first dose was given 2 weeks after stopping lamivudine and the intravenous administration of anti-HBs immunoglobulins. The latter was continued throughout the study and follow-up period to maintain an anti-HBs titre >100 IU/L. Results At the end of both the first and the second vaccination cycle none of the patients developed an anti-HBs titre greater than the basal anti-HBs titre. Conclusion These data confirm and expand our previous data on the lack of effectiveness of conventional recombinant hepatitis B virus vaccination in liver transplant recipients.

Published
2006
Full Text
View/download PDF

11. HBV-HDV co-infection constrains HBV genetic evolution in HBsAg

Author

A. Battisti, E. Nebuloso, L. Sarmati, Maria Stanzione, V. Svicher, G. De Sanctis, Mario Angelico, Nicola Coppola, Giuseppina Cappiello, R. Salpini, Michela Pollicita, Alberto Spanò, Luna Colagrossi, Aldo Bertoli, Pascale Trimoulet, Carmine Minichini, Caterina Pasquazzi, A. Barlattani, Ilaria Lenci, R. Longo, Leonardo Baiocchi, Claudio Maria Mastroianni, Rossana Scutari, C.F. Perno, M. Andreoni, T. Mari, Vincenzo Malagnino, Alfonso Galeota Lanza, G. Stornaiuolo, Massimo Marignani, Miriam Lichtner, Hervé Fleury, and N. Iapadre

Subjects
not available, HBsAg, Hepatology, business.industry, Genetic Evolution, Gastroenterology, Medicine, Biology, business, Virology, Co infection
Published
2016
Full Text
View/download PDF

12. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting

Author

C.F. Perno, F. Chiesara, D. Di Paolo, V. Gerardi, Alessandra Moretti, Francesca Ceccherini-Silberstein, Anna Claudia Pellicelli, Valeria Cento, C. Masetti, Paolo Rossi, Francesco Santopaolo, M. Siciliano, Mario Angelico, L. Fondacaro, Martina Milana, Raffaella Lionetti, Ilaria Lenci, and Gianpiero D’Offizi

Subjects
Liver disease, medicine.medical_specialty, Hepatology, business.industry, First line, Internal medicine, Gastroenterology, medicine, medicine.disease, business, Virology, Treatment failure
Published
2016
Full Text
View/download PDF

13. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

Author

Carlo Magni, Francesca Ceccherini-Silberstein, M. Puoti, Claudio Maria Mastroianni, A. Di Biagio, Marco Romano, Filomena Morisco, Giustino Parruti, Antonio Gasbarrini, Gloria Taliani, M. Siciliano, Simona Landonio, V.C. Di Maio, Martina Milana, Laura Gianserra, F. Deodati, Caterina Pasquazzi, M. Andreoni, J. Vecchiet, Valeria Cento, L. Lambiase, Marianna Aragri, Simona Francioso, E. D’Amico, Gabriella d'Ettorre, Giuliano Rizzardini, D. Di Paolo, Antonio Grieco, F. De Leonardis, A. Manunta, Ivana Maida, Anna Claudia Pellicelli, Mario Angelico, K. Yu La Rosa, Miriam Lichtner, P. Cacciatore, Cesare Sarrecchia, F.P. Antonucci, Aldo Bertoli, Valeria Micheli, Antonio Picciotto, Dante Romagnoli, Savino Bruno, Laura Ambra Nicolini, Ilaria Lenci, C.F. Perno, Marco Ciotti, Lorenzo Nosotti, Simona Marenco, Elisabetta Teti, M. Tontodonati, Maria Stella Mura, R. Campoli, Nicola Caporaso, S. Grieco, Sergio Babudieri, and Umberto Vespasiani-Gentilucci

Subjects
Genetics, chemistry.chemical_compound, NS3, Hepatology, chemistry, Direct sequencing, Genotype, Gastroenterology, Clinical significance, Biology, NS5A, NS5B, Direct acting
Published
2016
Full Text
View/download PDF

14. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

Author

Antonio Craxì, Filomena Morisco, M. Puoti, V.C. Di Maio, Nicola Caporaso, Anna Claudia Pellicelli, Francesca Ceccherini-Silberstein, M. Paoloni, Maria Stella Mura, G.B. Gaeta, F.P. Antonucci, Vincenza Calvaruso, R. Campoli, Gianluca Brancaccio, D. Di Paolo, Dante Romagnoli, Antonio Grieco, K. Yu La Rosa, Stefano Brillanti, Valeria Cento, Caterina Pasquazzi, Ilaria Lenci, Manuela Merli, Simona Francioso, M.C. Sorbo, M. Melis, Marco Biolato, C.F. Perno, Marianna Aragri, Aldo Bertoli, Gabriella Verucchi, Sergio Babudieri, V. Pisani, Mario Angelico, Francesca Donato, and J. Vecchiet

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DIRECT ACTING ANTIVIRALS, Virological failure, Surgery, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, 030211 gastroenterology & hepatology, In patient, business
Published
2016
Full Text
View/download PDF

15. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?

Author

F. Antenucci, C. Masetti, Plinio Rossi, Francesco Santopaolo, A. Brega, D. Di Paolo, A. Pecchioli, Ilaria Lenci, S. Cucchiarelli, Simona Francioso, T. Marianelli, F. De Leonardis, S. Di Nardi, A. Bosa, Mario Angelico, Martina Milana, and Leonardo Baiocchi

Subjects
Alpha fetoprotein levels, medicine.medical_specialty, Reduced risk, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, medicine, medicine.disease, business, Direct acting
Published
2017
Full Text
View/download PDF

16. Natural HCV resistance is common in Italy and differently associated to genotypes

Author

Simona Landonio, Barbara Menzaghi, Giustino Parruti, T. Ruggiero, Valeria Cento, Francesca Ceccherini-Silberstein, Ilaria Lenci, M. Melis, Giuliano Rizzardini, Antonio Gasbarrini, P. Cacciatore, V. Pace Palitti, M.C. Sorbo, Ennio Polilli, Martina Milana, Alessandro Pieri, Laura Gianserra, Anna Claudia Pellicelli, P. Andreone, C. Masetti, Bianca Bruzzone, Simona Marenco, Elisabetta Teti, M. Andreoni, Gloria Taliani, Aldo Bertoli, Elisa Biliotti, Miriam Lichtner, Nicola Coppola, Vincenza Calvaruso, Fausto Baldanti, Stefania Paolucci, C.F. Perno, Carlo Magni, Sergio Babudieri, Valeria Micheli, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Dante Romagnoli, Laura Ambra Nicolini, Mario Angelico, Loredana Sarmati, M. Siciliano, M. Puoti, N. Iapadre, Marianna Aragri, Vincenzo Vullo, Caterina Pasquazzi, and F. De Leonardis

Subjects
0301 basic medicine, Genetics, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Hepatology, Resistance (ecology), business.industry, Genotype, Gastroenterology, Medicine, 030211 gastroenterology & hepatology, business
Published
2017
Full Text
View/download PDF

17. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease

Author

A. Brega, T. Marianelli, Ilaria Lenci, C. Masetti, Francesco Santopaolo, F. Antenucci, F. De Leonardis, D. Di Paolo, Plinio Rossi, A. Pecchioli, Leonardo Baiocchi, Mario Angelico, S. Di Nardi, Simona Francioso, Martina Milana, and A. Bosa

Subjects
Nephrology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cohort, Gastroenterology, medicine, Renal function, medicine.disease, business, Direct acting, Kidney disease
Published
2017
Full Text
View/download PDF

18. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?

Author

A. Bosa, D. Di Paolo, Ilaria Lenci, Simona Francioso, S. Cucchiarelli, C. Masetti, Francesco Santopaolo, Martina Milana, Leonardo Baiocchi, F. De Leonardis, Mario Angelico, and Paolo Rossi

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Gastroenterology, Hcv recurrence, Virology, Virological response, Peg interferon, Internal medicine, Genotype, Medicine, business, After treatment, medicine.drug
Published
2016
Full Text
View/download PDF

19. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients

Author

Francesca Ceccherini-Silberstein, L. Carioti, V. Cento, Maria Concetta Bellocchi, Ilaria Lenci, Tommaso Maria Manzia, M. Manuelli, Martina Milana, G. Tisone, Daniele Sforza, F. De Leonardis, D. Di Paolo, F.P. Antonucci, Mario Angelico, M.C. Sorbo, and C.F. Perno

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, business
Published
2016
Full Text
View/download PDF

20. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

Author

Giustino Parruti, C.F. Perno, Francesca Ceccherini-Silberstein, Fabio Continenza, M. Puoti, V.C. Di Maio, S. Bruno, Cesare Sarrecchia, Carlo Magni, Daniele Armenia, J. Vecchiet, Mario Angelico, L. Carioti, Giuliano Rizzardini, D. Di Paolo, F. De Luca, Sergio Babudieri, Ilaria Lenci, F. De Leonardis, M. Andreoni, Marianna Aragri, M. Tontodonati, Valeria Micheli, A. De Maria, Antonio Picciotto, Maria Concetta Bellocchi, Maria Stella Mura, Valeria Cento, Ennio Polilli, Lorenzo Nosotti, Simona Francioso, Aldo Bertoli, F.P. Antonucci, and A. Manunta

Subjects
Standard Population, Hepatology, business.industry, Gastroenterology, Ultra deep sequencing, Virology, Telaprevir, chemistry.chemical_compound, chemistry, Boceprevir, Added value, medicine, business, medicine.drug
Published
2014
Full Text
View/download PDF

21. Transarterial Chemoocclusion (Taco) With Degradable-Starch-Microsphere In Unresecable Hepatocellular Carcinoma: A Prospective Pilot-Study

Author

A. Brega, Francesco Santopaolo, Ilaria Lenci, Simona Francioso, Martina Milana, Fabrizio Chegai, Mario Angelico, and Antonio Orlacchio

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Medical care, Microsphere, Stable Disease, Internal medicine, Hepatocellular carcinoma, Cholecystitis, medicine, Doxorubicin, Liver function, Artery occlusion, business, medicine.drug
Abstract

Background: According to BCLC algorithm, Transarterial Chemoembolization is recommended for unresecable hepatocellular carcinoma (HCC) in patients with preserved liver function. The intraarterial chemotherapy with transient artery occlusion could be a valid treatment alternative in patients with high-risk of liver failure. Aim of the present study was to evaluate efficacy and safety of TACO using Degradable-Starch-Microspheres (DSM) in patients with unresecable HCC. Methods We prospectively enrolled 24 cirrhotic patients (21/3M/F, mean age 66.3±10.5 years) with unresecable HCC, to be treated with three consecutives DSM-TACO at 5-week intervals. Chemotherapy drug was Doxorubicin Chloridrate (50mg/m2) mixed with 275mg DSM (Embocept®S, PharmaCept). Liver function before and after treatmentswas evaluatedwith Child Pugh and MELD scores. Treatment responsewas assessed by CT-scan 4weeks after procedures according to mRECIST criteria. Results: Overall, Complete Response (CR) was observed in 5/24 (20.8%), 9/24 (37.5%) and14/24 (58.3%)pts after thefirst, the second and the third procedure, respectively. No patient showed Stable Disease or Disease Progression at the end of the study. Patients withmonolobar disease (14/24: 58.3%) showed significant CR after the 1st procedure compared with bilobar HCC localization (5/14 vs 0/10; p=0.017). At the end, CR did not differ between mono or bilobar disease (9/14: 64.2% vs 5/10: 50%; p=ns). Drop-outs occurred in 8 patients (33.3%): 4 after the 1st treatment (3 worsened liver function, 1 liver transplanted), 4 after the 2nd treatment (2worsened liver function, 1 liver transplanted, 1 non compliance). Postembolization syndromewas observed in 9 (37.5%), in 4 (16.6%) requiring extended hospitalization. One patient had cholecystitis resolved with medical care. Conclusions: DSM-TACO offers a valid TACE alternative in patients with unresecable HCC. Careful patients selection is required to avoid liver failure in patients with border-line liver compensation. Further investigation to define DSM-TACO effects on survival is warranted.

Published
2015
Full Text
View/download PDF

22. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors

Author

Valeria Micheli, Antonio Picciotto, Aldo Bertoli, Massimo Levrero, C.F. Perno, Ilaria Lenci, Francesca Guerrieri, F.P. Antonucci, Mario Angelico, F. De Leonardis, M. Andreoni, Lorenzo Nosotti, Giustino Parruti, Simona Francioso, Marianna Aragri, M. Santoro, Giuliano Rizzardini, Carlo Magni, F. De Luca, Ludovica Calvo, Valeria Cento, A. Manunta, J. Vecchiet, Francesca Ceccherini-Silberstein, S. Bruno, Daniele Armenia, Maria Concetta Bellocchi, D. Di Paolo, Cesare Sarrecchia, Filomena Morisco, M. Puoti, V.C. Di Maio, Sergio Babudieri, M. Tontodonati, Ennio Polilli, Maria Stella Mura, Simona Marenco, and L. Carioti

Subjects
Protease, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, Clinical significance, business, Bioinformatics, Baseline (configuration management), DNA sequencing
Published
2015
Full Text
View/download PDF

23. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation

Author

G. Tisone, Ilaria Lenci, S. Cucchiarelli, D. Di Paolo, Mario Angelico, Valeria Cento, F.P. Antonucci, Martina Milana, F. Ceccherini Silberstein, V.C. Di Maio, Emiliano Giardina, F. De Luca, and C.F. Perno

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Hcv recurrence, Liver transplantation, medicine.disease, Fibrosis, Internal medicine, medicine, In patient, business, NS5A
Published
2013
Full Text
View/download PDF

24. F-19 Correlation between ultrasonographic Hamaguchi score, insulin resistance, obesity and fatty liver indexes in patients affected by NAFLD

Author

C. Francia, Leonardo Baiocchi, Roberto Cecere, M. Delle Monache, F. De Leonardis, and Ilaria Lenci

Subjects
medicine.medical_specialty, Hepatology, business.industry, Fatty liver, Gastroenterology, medicine.disease, Obesity, Correlation, Insulin resistance, Internal medicine, medicine, In patient, business
Published
2013
Full Text
View/download PDF

25. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors

Author

Giustino Parruti, Gloria Taliani, Simona Francioso, Ilaria Lenci, F.P. Antonucci, Claudio Maria Mastroianni, Simona Landonio, Laura Ambra Nicolini, Ivana Maida, Valeria Micheli, Antonio Picciotto, D. Di Paolo, Giuliano Rizzardini, Lorenzo Nosotti, F. De Leonardis, Marco Massari, Antonio Gasbarrini, Anna Claudia Pellicelli, Sergio Babudieri, A. Manunta, Jacopo Vecchiet, Francesca Ceccherini-Silberstein, M. Tontodonati, A. De Maria, Ennio Polilli, Maria Stella Mura, Tamara Ursini, Cesare Sarrecchia, Simona Marenco, A. Di Biagio, Marianna Aragri, Massimo Andreoni, Mario Angelico, Valeria Cento, Fosca Niero, Alessandra Mangia, Annalisa Tortora, Alessandro Mancon, M. Siciliano, V.C. Di Maio, Carlo Federico Perno, Carlo Magni, Claudio Viscoli, and Aldo Bertoli

Subjects
NS3, Protease, Hepatology, Resistance development, Viral dynamics, business.industry, medicine.medical_treatment, Gastroenterology, Medicine, business, Virology, First generation
Published
2014
Full Text
View/download PDF

27. Chronic hepatitis B vaccine therapy: Hepatitis B vaccination combined with hepatitis B immunoglobulins and lamivudine

Author

C. Cerocchi, Paola Piccolo, M.O. Trinito, D. Di Paolo, Mario Angelico, and Ilaria Lenci

Subjects
Hepatology, biology, business.industry, Gastroenterology, Lamivudine, Hepatitis B, medicine.disease, Virology, Vaccine therapy, Chronic hepatitis, Hepatitis b vaccination, biology.protein, Medicine, Antibody, business, medicine.drug
Published
2008
Full Text
View/download PDF

28. One-year extended anti-HBV vaccination with an MPL-adjuvanted vaccine combined with anti-HBs immunoglobulins in patients liver transplanted for HBV-related cirrhosis

Author

M. Berlanda, Mario Angelico, Giuseppe Tisone, D. Di Paolo, C. Cerocchi, Ilaria Lenci, and M.O. Trinito

Subjects
Anti hbs, Cirrhosis, Hepatology, biology, business.industry, Gastroenterology, medicine.disease, Virology, Vaccination, Immunology, biology.protein, Medicine, In patient, Antibody, business, Anti hbv
Published
2007
Full Text
View/download PDF

29. Metabolic syndrome and liver transplantation: Incidence and risk factors

Author

Francesco Angelico, Ilaria Lenci, Mario Angelico, D. Di Paolo, Giuseppe Tisone, Simona Francioso, and Cristiana Almerighi

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Incidence (epidemiology), Gastroenterology, Liver transplantation, medicine.disease, Internal medicine, medicine, Metabolic syndrome, business
Published
2007
Full Text
View/download PDF

30. OC.03.1 EARLY DYNAMIC EVALUATION OF THE NS3 HCV-GENOME REGION DURING TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1: PRELIMINARY RESULTS FROM THE SCANNER STUDY

Author

Ilaria Lenci, S. Cucchiarelli, C.F. Perno, V.C. Di Maio, Valeria Cento, Cesare Sarrecchia, Lorenzo Nosotti, F. Ceccherini-Silberstein, D. Di Paolo, F. Antenucci, F. De Leonardis, Mario Angelico, F. De Luca, Carmen Mirabelli, Simona Francioso, and M. Mapfumo

Subjects
NS3, Hepatology, business.industry, Gastroenterology, Virology, Genome, Telaprevir, chemistry.chemical_compound, Chronic hepatitis, chemistry, Boceprevir, Genotype, medicine, In patient, business, medicine.drug
Published
2013
Full Text
View/download PDF

31. P.11.22 HCV GENOME VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION: DOES THE VIRAL DIVERSITY PLAY A ROLE ON FIBROSIS PROGRESSION?

Author

Valeria Cento, C.F. Perno, Ilaria Lenci, Mario Angelico, S. Cucchiarelli, F.P. Antonucci, D. Di Paolo, Martina Milana, F. Ceccherini-Silberstein, V.C. Di Maio, F. De Luca, and Emiliano Giardina

Subjects
Hepatology, business.industry, media_common.quotation_subject, medicine.medical_treatment, Gastroenterology, Hcv recurrence, Liver transplantation, medicine.disease, Virology, Genome, Fibrosis, Immunology, Medicine, business, Diversity (politics), media_common
Published
2013
Full Text
View/download PDF

32. F-01 Baseline and early dynamic evaluation of HCV NS3-resistance

Author

Cesare Sarrecchia, Mario Angelico, D. Di Paolo, C.F. Perno, F.P. Antonucci, Valeria Cento, M. Mapfumo, F. De Leonardis, Aldo Bertoli, F. De Luca, Ilaria Lenci, S. Cucchiarelli, V.C. Di Maio, F. Ceccherini Silberstein, Simona Francioso, Lorenzo Nosotti, and F. Antenucci

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Baseline (configuration management), business
Published
2013
Full Text
View/download PDF

33. One year follow-up after an extended anti-HBV vaccination with an MPL-adjuvanted vaccine combined with HBIG in patients liver transplanted for HBV-related cirrhosis

Author

C. Cerocchi, M. Berlanda, Ilaria Lenci, D. Di Paolo, Mario Angelico, and Giuseppe Tisone

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, One year follow up, business.industry, Gastroenterology, medicine.disease, Vaccination, Internal medicine, medicine, In patient, business, Anti hbv
Published
2009
Full Text
View/download PDF

34. ONE YEAR FOLLOW-UP AFTER AN EXTENDED ANTI-HBV VACCINATION WITH AN MPL-ADJUVANTED VACCINE COMBINED WITH ANTI-HBS IMMUNOGLOBULINS IN PATIENTS LIVER TRANSPLANTED FOR HBV-RELATED CIRRHOSIS

Author

C. Cerocchi, G. Tisone, Mario Angelico, D. Di Paolo, Ilaria Lenci, and M. Berlanda

Subjects
Anti hbs, Cirrhosis, Hepatology, One year follow up, biology, business.industry, Gastroenterology, medicine.disease, Vaccination, Immunology, biology.protein, Medicine, In patient, Antibody, business, Anti hbv
Published
2009
Full Text
View/download PDF

35. Weaning of HBV prophylaxis after liver transplantation: Preliminary results in patients with undetectable cccDNA in liver tissue

Author

Mario Angelico, A. Salso, C.F. Perno, F. Marcuccilli, Giuseppe Tisone, D Dipaolo, Ilaria Lenci, S. Cucchiarelli, and F. Riccobelli

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, cccDNA, Liver transplantation, Liver tissue, Internal medicine, medicine, Weaning, In patient, business
Published
2009
Full Text
View/download PDF

37. RELATIONSHIP BETWEEN GH/IGF-1 AXIS, GRAFT RECOVERY AND EARLY SURVIVORSHIP IN PATIENTS UNDERGOING LIVER TRANSPLANTATION

Author

F. Riccobelli, Ilaria Lenci, S. Cucchiarelli, A. Salso, Cristiana Almerighi, G. Tisone, Simona Francioso, Leonardo Baiocchi, Mario Angelico, and Marco Carbone

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Survivorship curve, Gastroenterology, medicine, In patient, Liver transplantation, business, Surgery
Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results